Avita Medical Ltd (RCEL), now known as Avita Therapeutics, Inc., is a global regenerative medicine company that specializes in the treatment of wounds and skin defects. This healthcare firm is publicly traded and is headquartered in Valencia, California. Founded in 2008, it has a market capitalisation of around $400 million.
The company conducts groundbreaking research and development within the field of regenerative medicine, primarily focusing on creating new treatments for burns, chronic wounds, and aesthetic indications. Avita Medical Ltd's innovation trajectory is fuelled by a resilient commitment to address unmet medical needs and enhance patient lives, leveraging its innovative technology platforms.
Avita's flagship product, Recell System, is a pioneering breakthrough that uses a small sample of the patient's own skin to create Spray-On Skin™ Cells to rehabilitate and improve the appearance of severe burns. Recell System's approval in many regions such as the U.S, Europe and Australia, reveals the product’s potential and the robustness of Avita's scientific research, this resulted in a notable market leading position.
Apart from its groundbreaking product, the company places great emphasis on clinical trials, launching numerous studies to further demonstrate and validate the efficacy of its Recell System. This commitment to robust scientific research not only reinforces the value proposition of its existing products but also paves the way for future innovations.
Moreover, Avita Medical's strong financial standing is reflective of its ability to efficiently use resources to drive growth. This continued financial strength, coupled with its rich pipeline of potential products, positions it well for future expansion.
Over the years, Avita Medical Ltd has evolved into a staunch player in the regenerative medicine industry. The success of the company is testament to its relentless pursuit of innovation, commitment to scientific research, and the ability to address gaps in patient care with novel solutions. Hence, it casts an optimistic outlook on the continued growth and expanding reach of Avita Medical Ltd in the field of regenerative medicine.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends

AVITA Medical announced complete results from its Cohealyx I study, demonstrating significantly earlier readiness for skin grafting and improved six-month healing outcomes in full-thickness wounds. The study showed a median graft readiness of 11 days, with 72% of wounds ready within two weeks, and reported no Cohealyx-related adverse events, along with improving scar scores. These findings support the use of Cohealyx for preparing complex wounds for skin grafting, enhancing confidence among clinicians.

Avita Medical (NASDAQ:RCEL) recently received an upgrade from "hold" to "buy" by Wall Street Zen. This aligns with other analysts, resulting in a "Moderate Buy" consensus rating and a target price of $16.60. The company also reported strong quarterly earnings, beating analyst estimates for both EPS and revenue.

TD Cowen has increased its price target for Avita Medical (NASDAQ:RCEL) to $22.00, up from $20.00, while maintaining a "buy" rating, indicating a potential upside of 25.93%. This positive outlook aligns with the company's recent strong quarterly earnings, where it surpassed analyst expectations for both EPS and revenue. Other brokerages have also adjusted their ratings and price targets for RCEL, contributing to a "Moderate Buy" consensus rating with an average target price of $16.60.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) is set to host an investor webinar briefing and presentation on November 11, 2026, featuring CEO Cary Vance and CFO David O'Toole. The briefing will cover financial and business results from the recent third-quarter 2026 earnings webcast, concluding with a Q&A session for shareholders and prospective investors. A replay of the event will be available on the company's website following the presentation.

AVITA Medical reported a 53% year-over-year revenue increase to $26.1 million in Q3 2026, driven by strong adoption of its RECELL system and growth in Cohealyx. The company significantly reduced its cash use and raised its full-year revenue guidance to $92-$94 million, expecting to achieve cash flow breakeven in Q4. Management emphasized expanding its commercial footprint in burn and trauma centers and leveraging its integrated wound care portfolio.